Reunion Neuroscience (TSX:REUN) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

REUN Stoklara Genel Bakış

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. Daha fazla detay

REUN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 14% oranında düşmesi öngörülüyor

Geliri 1 milyon ABD dolarından az ( CA$0 )

+ 2 daha fazla risk

Reunion Neuroscience Inc. Rakipler

Willow Biosciences

TSX:WLLW

CA$11.5m

Medicure

TSXV:MPH

CA$9.4m

COSCIENS Biopharma

TSX:CSCI

CA$13.3m

Covalon Technologies

TSXV:COV

CA$101.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Reunion Neuroscience
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$1.42
52 Haftanın En Yüksek Seviyesi	CA$9.44
52 Haftanın En Düşük Seviyesi	CA$0.83
Beta	4.21
11 Aylık Değişim	-2.07%
3 Aylık Değişim	40.59%
1 Yıllık Değişim	-72.95%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-89.48%

Son Haberler & Güncellemeler

Recent updates

Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

Aug 01

We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

Apr 03

Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Jan 17

Hissedar Getirileri

	REUN	CA Biotechs	CA Pazar
7D	-3.4%	0.6%	1.7%
1Y	-73.0%	-4.6%	24.0%

Getiri vs. Endüstri: REUN geçen yıl % -4.6 oranında getiri sağlayan Canadian Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: REUN geçen yıl % 24 oranında getiri sağlayan Canadian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is REUN's price volatile compared to industry and market?
REUN volatility
REUN Average Weekly Movement	18.6%
Biotechs Industry Average Movement	11.8%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: REUN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: REUN 'nin haftalık oynaklığı ( 19% ) geçen yıl boyunca sabit kaldı, ancak hala Canadian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	16	Greg Mayes	reunionneuro.com

Reunion Neuroscience Inc. Temel Bilgiler Özeti

Reunion Neuroscience'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REUN temel i̇stati̇sti̇kler
Piyasa değeri	CA$16.64m
Kazançlar(TTM)	-CA$38.10m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.4x

F/K Oranı

REUN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REUN gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$38.10m
Kazançlar	-CA$38.10m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.25
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

REUN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company has been acquired

REUN Stoklara Genel Bakış

Risk Analizi

Reunion Neuroscience Inc. Rakipler

TSX:WLLW

CA$11.5m

TSXV:MPH

CA$9.4m

TSX:CSCI

CA$13.3m

TSXV:COV

CA$101.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Recent updates

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$47.75

High number of new directors

Reunion Neuroscience Inc. to Report Q2, 2023 Results on Nov 14, 2022

High number of new and inexperienced directors

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience Inc. Appoints Greg Mayes as President

Consensus forecasts updated

High number of new and inexperienced directors

Field Trip Health Ltd., Annual General Meeting, Sep 29, 2022

Field Trip Health Ltd. completed the Split-Off of Field Trip Health & Wellness Ltd.

Field Trip Health Ltd. to Report Q1, 2023 Results on Aug 15, 2022

Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

Price target increased to CA$14.25

Field Trip Health Ltd. Announces First Successful Dosings in the Phase 1 Clinical Study Entitled A Double-Blind

Field Trip Health Ltd. to Report Q4, 2022 Results on Jun 29, 2022

Price target decreased to CA$11.90

High number of new directors

Field Trip Health Ltd. Receives U.S. Patent Covering Novel Psychedelic Molecule FT-104

We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

High number of new and inexperienced directors

Consensus revenue estimates fall by 17%

Price target decreased to CA$11.90

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Field Trip Health Ltd. to Report Q3, 2022 Results on Feb 15, 2022

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Field Trip Launches Site Management Organization Services

Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.70 loss per share (vs CA$2.03 loss in FY 2020)

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Founder recently bought CA$250k worth of stock

Field Trip Health Ltd. has completed a Follow-on Equity Offering in the amount of CAD 82.875 million.

New 90-day high: CA$7.99

Field Trip Health Ltd. to Report Q3, 2021 Results on Feb 16, 2021

Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Field Trip Health Ltd. Announces Participation in a Maps-Sponsored Multi-Site Study of Mdma-Assisted Therapy to Treat Eating Disorders

Field Trip Health Ltd. has completed a Composite Units Offering in the amount of CAD 17.406 million.

Field Trip Health Ltd. to Report Q2, 2021 Results on Nov 30, 2020

Field Trip Health Ltd. and Whoop Announces Partnership to Measure Effect of Psychedelic Therapies on Physiology and Mental Health

Field Trip Health Ltd. Provides Update on FT-104

Heroic Hearts Project and Field Trip Health Ltd. Enter into A Strategic Relationship to Increase Legal Psychedelic Therapy Access for Military Veterans in North America

Field Trip Health Ltd. Announces Addition of Andrew Weil, M.D to Its Medical Advisory Board

Hissedar Getirileri

Fiyat Oynaklığı